Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 13, 2012-11 ,pp. : 1345-1358

Bentham Science Publishers

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki   Abe Masanori   Higuchi Terumi   Mizuno Mari   Suzuki Hiroko   Matsumoto Shiro   Ito Midori   Maruyama Noriaki   Okada Kazuyoshi   Soma Masayoshi  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

By Pratley Richard E  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

By  

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 71-87

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

By Someya Yuka  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 377, Iss. 3, 2008-05 ,pp. : 209-217

Springer Publishing Company

Access to resources Recommend Favorite